Apologizes, missed part of the post. Rest as foll

Quote:

---

Brazil says interim analysis with significant p value will give an EUA.

Cost savings by running trial in Brazil.

CYDY funds the trial and we own the data.

CD-12 study data used to design Brazil trials CD-16/17

NIH thinking ???

No CD-16/17 trial in U.S.

Will explain Brazil trial differences.

Hungary: global distribution plan coming for the world!

Amerex is a CRO. Einstein is a hospital and an academic research organization. They have a network of facilities with the backing of a research facility that moves like a business.

UK: accelerated rolling review is going to be granted to Cytodyn

FDA denied us a EUA after we applied for it.

OLE data: small number, not randomized, so not very useful.

CD-12 results will be published in a journal.

OLE results will be published.

On target for finishing Long Hauler trial. Interested in bio marker study.

Law Firms have until May 17th to file a formal complaint. No letters to SEC other than for CITRON.

Partnerships: cannot discuss. However, they are in discussions...the valuation is too high right now.

No requests from the WHO.

No Big Pharma conspiracy.

What can we do to stop these fake lawsuits? Keep generating data, the stock price will take care of itself. Scientists are blown away by are data.

Will look at donations at a case by case basis.

How to get LL in US: Emergency IND, RIGHT TO TRY

2017/18 Spent 30M to get 1.2M vials (saved a 470M share dilution). Have raised, 190M for only 33M share dilution! Liquidity position is at an all time high. Dilution is not an issue. Enough funding to get to the end of the year for everything we have planned.

NASDAQ: money, and share price...both depends on science. These trials in Brazil are tremendously valuable and NP sees them as a Godsend.

---